Questions arise over drug firms' lobbying

Market observers say that the whole domestic pharmaceutical industry are drawn into the vortex of the illegal lobbying of multinational pharmaceutical firms, amidst the government reservation of a set of drug pricing policies to discourage the use of high-priced drugs, such as reference pricing system and drug re-evaluation system.

1) Alleged pressure of the U.S. administration

Fueled by ...